Notable companies
The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).
Industry description
The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index.
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
Market Cap
The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.54B. The market cap for tickers in the group ranges from 60.72M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is STRO at 60.72M.
High and low price notable news
The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was 60%. For the same ETF, the average monthly price growth was 68%, and the average quarterly price growth was 86%. STRO experienced the highest price growth at 67%, while YMAB experienced the biggest fall at -9%.
Volume
The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was 25%. For the same stocks of the ETF, the average monthly volume growth was 37% and the average quarterly volume growth was 10%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 73
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)